Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 13, 2020 and accepted by EDGAR at Nov 13, 2020, 17:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $9.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $27.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $2.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $6.4m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $4.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$4.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $75.2k | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $227.7k | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $3.7k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $45.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$481.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$2.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 15,134,583 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 15,206,179 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $4.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $95.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2020-01-01 to 2020-09-30 | $1.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-09-30 | $26.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $48.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $96.0m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $23.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $48.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $47.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-20-016446. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.